Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3731579 in Healthy Volunteers
NCT06716190Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3731579 (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of Any Treatment-emergent Adverse Event Assessed as Drug-related by the Investigator at 19 days. Started Dec 2024; status: terminated.
02
Drugs
BI 3731579
Beyond the preview
Go deeper on NCT06716190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716190.